跳至主要内容
临床试验/NCT00100971
NCT00100971终止1 期

Dendritic/Leukemic Fusion Cell Vaccine Therapy For AML Patients In First Remission; A Phase I Clinical Trial

Boston Medical Center2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2004年4月1日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
终止
入组人数
9
试验地点
2

研究概览

简要总结

RATIONALE: Vaccines made from a person's white blood cells and cancer cells may make the body build an effective immune response to kill cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with acute myeloid leukemia.

详细描述

OBJECTIVES:

Primary

  • Determine the maximum tolerated dose of autologous dendritic and leukemic fusion cell vaccine in patients with acute myeloid leukemia.
  • Determine the toxicity of this vaccine in these patients.

Secondary

  • Determine whether cellular immunity can be induced by this vaccine in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • DISEASE CHARACTERISTICS:
  • Diagnosis of acute myeloid leukemia (AML) by bone marrow biopsy
  • Newly diagnosed
  • Must have adequate dendritic cells and AML blasts isolated from bone marrow and/or peripheral blood
  • No clinical evidence of CNS leukemia
  • PATIENT CHARACTERISTICS:
  • 18 and over
  • Performance status
  • Not specified
  • Life expectancy
  • Not specified
  • Hematopoietic
  • Not specified
  • Not specified
  • Not specified
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • HIV negative
  • No clinically significant autoimmune disease
  • No other active malignancy except nonmelanoma skin cancer
  • PRIOR CONCURRENT THERAPY:
  • Biologic therapy
  • More than 3 months since prior immunotherapy
  • Chemotherapy
  • Not specified
  • Endocrine therapy
  • Not specified
  • Radiotherapy
  • Not specified
  • Not specified

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验